Effect of Genetic Variation in the Transporter, OAT3, on the Renal Secretion of Cefotaxime
| Status: | Archived |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
In the proposed study, we plan to use a genotype to phenotype strategy to study the role of
the organic anion transporter, OAT3, in drug response. More specifically we will examine
the contribution of OAT3 to the renal clearance of anionic drugs such as cefotaxime by
studying individuals with a non-functional (or poorly-functional) variant of OAT3.
We found this trial at
1
site
San Francisco General Hospital San Francisco General Hospital and Trauma Center (SFGH) is an essential...
Click here to add this to my saved trials
